P-037 BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 study
Omar Nadeem(Harvard University), Susan Bal(University of Alabama at Birmingham Hospital), Myo Htut(City Of Hope National Medical Center), Allison Kaeding(Bristol-Myers Squibb (United States)), Daniel Egan, Larry D. Anderson(Dana-Farber Cancer Institute), Adriana Rossi(Icahn School of Medicine at Mount Sinai), Tara Gregory(Colorado Blood Cancer Institute), Jesús G. Berdeja(Tennessee Oncology), Mehmet H. Kocoglu(University of Maryland, Baltimore), Michael R. Burgess(Bristol-Myers Squibb (United States)), Hongxiang Hu(Bristol-Myers Squibb (United States)), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Luciano J. Costa(University of Alabama at Birmingham), Yanping Chen(Bristol-Myers Squibb (United States)), Lisa M. Kelly(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505